krn 2

KRN2 has potential to treat NFAT5-mediated Chronic Arthritis. KRN2 is a selective inhibitor of nuclear factor of activated T cells (NFAT5), with an IC50 of 100 nM.

KRN2 bromide 是有效的、选择性的 T 细胞激活核因子 (NFAT5) 的抑制剂 (IC50= 100 nM)。KRN2 bromide 可用于研究 NFAT5-介导的慢性关节炎。

KRN7000 analog 2 作为一种iNKT激动剂，展示了其在抗肿瘤及疫苗佐剂研究中的潜在应用。

Burosumab(KRN23) 是一种靶向成纤维细胞生长因子 23 （FGF23） 的人单克隆抗体，用于治疗皮肤骨骼低磷血症综合征（CSHS）和肿瘤诱导的骨软化症。

KRN-633 是一种 VEGFR 抑制剂，能够一种 VEGFR1 (IC50:170 nM)、VEGFR2 (IC50:160 nM)、VEGFR3 (IC50:125 nM)。

α-Galactosylceramide analog 8 (α-GalCer analog 8) is a triazole derivative of α-galactosylceramide. [1] It increases IL-2 secretion by DN32.D3 NKT hybridoma cells when co-cultured with CD1d-transfected RBL cells pre-loaded with α-GalCer analog 8 at a concentration of 32 ng ml. α-GalCer analog 8 (32 ng ml) induces IL-4 secretion to a greater extent than the synthetic α-GalCer KRN 7000 in mouse splenocytes in vitro and in mouse serum following administration of a 1 µg per animal dose, indicating a Th2 response.